MyTomorrows , the Netherlands-headquartered startup that has built a platform to help physicians and patients access drugs that are still in development, has raised €10 million in further funding. Leading the round is EQT Ventures, and Octopus Ventures, with participation from existing backers Balderton Capital, and Sofinnova Partners.
The Dutch startup wants to disrupt the way patients with unmet medical needs access development-stage treatments — drugs that are still undergoing clinical trials and working their way through a lengthy regulatory approval process, or are already approved in one country but not another.
Launched in 17 countries, the myTomorrows platform targets doctors and patients seeking information and access to nascent drugs while offering drug development companies a turn-key solution to run global early access programs.
